AEVI GENOMIC MEDICINE INC (GNMX) Covered Calls

You can sell covered calls on AEVI GENOMIC MEDICINE INC to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GNMX (prices last updated Fri 4:16 PM ET):

AEVI GENOMIC MEDICINE INC (GNMX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.16 +0.04 1.15 1.23 89K - 0.1B
Covered Calls For AEVI GENOMIC MEDICINE INC (GNMX)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Sep 21 2.5 0.00 1.23 0.0% 0.0%
Dec 21 2.5 0.05 1.18 4.2% 12.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.